APA (7th ed.) Citation

Maher, T. M., Kreuter, M., Lederer, D. J., Brown, K. K., Wuyts, W., Verbruggen, N., . . . Wijsenbeek, M. (2019). Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). BMJ Open Respiratory Research, 6, . https://doi.org/10.1136/bmjresp-2019-000422

Chicago Style (17th ed.) Citation

Maher, Toby M., et al. "Rationale, Design and Objectives of Two Phase III, Randomised, Placebo-controlled Studies of GLPG1690, a Novel Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (ISABELA 1 and 2)." BMJ Open Respiratory Research 6 (2019). https://doi.org/10.1136/bmjresp-2019-000422.

MLA (9th ed.) Citation

Maher, Toby M., et al. "Rationale, Design and Objectives of Two Phase III, Randomised, Placebo-controlled Studies of GLPG1690, a Novel Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (ISABELA 1 and 2)." BMJ Open Respiratory Research, vol. 6, 2019, https://doi.org/10.1136/bmjresp-2019-000422.